Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304353 | 1.00 | GNPAT (0.61) | GNPATFOLH1NOD1EPHX2C3AR1 | |
| SCHEMBL31503042 | 0.99 | GNPAT (0.60) | GNPATFOLH1NOD1EPHX2C3AR1 | |
| SCHEMBL17304356 | 0.93 | GNPAT (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304344 | 0.93 | GNPAT (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304345 | 0.92 | NOD1 (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304354 | 0.92 | NOD1 (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304349 | 0.92 | NOD1 (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304352 | 0.92 | NOD1 (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304347 | 0.92 | NOD1 (0.52) | GNPATFOLH1NOD1EPHX2NPY1R | |
| SCHEMBL17304348 | 0.92 | NOD1 (0.52) | GNPATFOLH1NOD1EPHX2NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148070-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH SA (CH) | 2023-05-11 | — | — | US | disclosed |
| WO-2021209345-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH SA (CH) | 2021-10-21 | — | — | WO | disclosed |
| US-11013704-B2 | Compounds supports hematopoietic stem cells and red blood cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-25 | — | — | US | disclosed |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | NANOSCIENCE FOR LIFE GMBH & COKG (DE) | 2019-03-26 | — | — | US | disclosed |
| EP-3152219-B1 | METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPOID PHASES | NANOSCIENCE FOR LIFE GMBH & CO KG (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-9994464-B2 | Method and devices for de-emulsifying and complexing organic compounds in emulsions | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9994464-B2 | Method and devices for de-emulsifying and complexing organic compounds in emulsions | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9932540-B2 | Method for refining lipid phases, and use | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-04-03 | — | — | US | disclosed |
| US-9932540-B2 | Method for refining lipid phases, and use | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-04-03 | — | — | US | disclosed |
| US-20170304240-A1 | NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-26 | — | — | US | disclosed |
| WO-2015185676-A1 | APPARATUS AND METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPID PHASES | NANOSCIENCE FOR LIFE GMBH & COKG (DE) | 2015-12-10 | — | — | WO | disclosed |
| EP-2952565-A1 | Device and method for recovering glycoglycerolipids and glycosphingolipids from lipid phases | Nanoscience for life GmbH & Co. KG (DE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015183545-A1 | NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181341-A1 | METHOD FOR REFINING LIPID PHASES, AND USE | DREI LILIEN PVG GMBH & CO. KG (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-9127233-B2 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by means of micro-or nanoemulsification | Dietz, Ulrich (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9127233-B2 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by means of micro-or nanoemulsification | Dietz, Ulrich (DE) | 2015-09-08 | — | — | US | disclosed |
| US-20130090488-A1 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2013-04-11 | — | — | US | disclosed |
| US-20130090488-A1 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2013-04-11 | — | — | US | disclosed |
| WO-2011160857-A2 | DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION | DIETZ ULRICH (DE) | 2011-12-29 | — | — | WO | disclosed |
| EP-2399885-A1 | Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification | Dietz, Ulrich (DE) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304240-A1 | NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS | EPOR, THPO, MCL1 | GNPAT 2435/4885FOLH1 1193/4885NOD1 4864/4885 |
| US-11013704-B2 | Compounds supports hematopoietic stem cells and red blood cells | EPOR, THPO, MCL1 | GNPAT 2056/4885FOLH1 1061/4885NOD1 4866/4885 |
| US-20230148070-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS | GLUL, TAS2R5, ARGLU1 | GNPAT 2591/4885FOLH1 705/4885NOD1 2494/4885 |
| US-10239906-B2 | Apparatus and method for obtaining glycoglycerolipids and glycosphingolipids from lipid phases | AGL, LIPA, MGLL | GNPAT 113/4885FOLH1 1223/4885NOD1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.